BackCancer Genetics Overview

Cancer Genetics Current Cash

Cancer Genetics's current cash is $2.4M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.44M

Peer average

Loading

Cancer Genetics Current Cash History

Loading

Cancer Genetics vs. peers: Current Cash Comparison

Loading

Cancer Genetics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

As of the most recent data (December 2020), CGIX shows a current cash of $2.4M. Scroll down for historical charts and peer comparison views.

Tracking CGIX's current cash over time shows whether Cancer Genetics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.4M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Cancer Genetics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $2.4M) with ownership activity and broader fundamentals.

Cancer Genetics's current cash is $2.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.